Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Other Publications
    • ajnr

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
  • For Authors
  • About Us
    • About AJNR
    • Editors
    • American Society of Neuroradiology
  • Submit a Manuscript
  • Podcasts
    • Subscribe on iTunes
    • Subscribe on Stitcher
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Review ArticleReview Articles
Open Access

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

L.C. Hygino da Cruz, I. Rodriguez, R.C. Domingues, E.L. Gasparetto and A.G. Sorensen
American Journal of Neuroradiology December 2011, 32 (11) 1978-1985; DOI: https://doi.org/10.3174/ajnr.A2397
L.C. Hygino da Cruz Jr
aFrom the Department of Radiology (L.C.H.C.), Clinics IRM, Clinica de Diagnóstico por Imagen and Multi-Imagem, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
I. Rodriguez
bImagen Médica Avanzada (I.R.), Madrid, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.C. Domingues
cClinics Clinica de Diagnóstico por Imagen and Multi-Imagem (R.C.D.), Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.L. Gasparetto
dDepartment of Radiology (E.L.G.), Clinics Clinica de Diagnóstico por Imagen and Multi-Imagem, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.G. Sorensen
eDepartment of Radiology, (A.G.S.), Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
Loading

References

  1. 1.↵
    1. Stupp R,
    2. Mason WP,
    3. van den Bent MJ,
    4. et al
    . Radiotheraphy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–96
    CrossRefPubMedWeb of Science
  2. 2.↵
    1. Macdonald DR,
    2. Cascino T,
    3. Schold SJ,
    4. et al
    . Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277–80
    Abstract
  3. 3.↵
    1. Wen PY,
    2. Macdonald DR,
    3. Reardon DA,
    4. et al
    . Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010;28:1963–72
    Abstract/FREE Full Text
  4. 4.↵
    1. Sorensen AG,
    2. Batchelor TT,
    3. Wen PY,
    4. et al
    . Response criteria for glioma. Nat Clin Pract Oncol 2008;5:634–44
    CrossRefPubMedWeb of Science
  5. 5.↵
    1. Brandsma D,
    2. van den Bent MJ
    . Pseudoprogression and pseudoresponse in the treatment of gliomas. Curr Opin Neurol 2009;22:633–38
    CrossRefPubMed
  6. 6.↵
    1. Kumar AJ,
    2. Leeds NE,
    3. Fuller GN,
    4. et al
    . Malignant gliomas: MR imaging spectrum of radiation therapy- and chemotherapy-induced necrosis of brain after treatment. Radiology 2000;217:377–84
    CrossRefPubMedWeb of Science
  7. 7.↵
    1. Ulmer S,
    2. Braga TA,
    3. Barker FG 2nd.,
    4. et al
    . Clinical and radiographic features of peritumoral infarction resection of glioblastoma. Neurology 2006:67:1668–70
    Abstract/FREE Full Text
  8. 8.↵
    1. de Wit MC,
    2. de Bruin HG,
    3. Eijkenboom W,
    4. et al
    . Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology 2004;63:535–37
    Abstract/FREE Full Text
  9. 9.↵
    1. Brandsma D,
    2. Stalpers L,
    3. Taal W,
    4. et al
    . Clinical features, mechanisms, and management of pseudoprogression in malignant glioma. Lancet Oncol 2008;9:453–61
    CrossRefPubMedWeb of Science
  10. 10.↵
    1. Taal W,
    2. Brandsma D,
    3. de Bruin HG,
    4. et al
    . Incidence of early pseudo-progression in cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 2008;113:405–10
    CrossRefPubMedWeb of Science
  11. 11.↵
    1. Brandes AA,
    2. Franceschi E,
    3. Tosoni A,
    4. et al
    . MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol 2008;26:2192–97
    Abstract/FREE Full Text
  12. 12.↵
    1. Brandes AA,
    2. Tosoni A,
    3. Franceschi E,
    4. et al
    . Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009;27:1275–79
    Abstract/FREE Full Text
  13. 13.↵
    1. Chamberlain MC
    . Pseudoprogression in glioblastoma. J Clin Oncol 2008;26:4359
    FREE Full Text
  14. 14.↵
    1. Chaski C,
    2. Neyns B,
    3. Michotte A,
    4. et al
    . Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surg Neurol 2009;72:423–28
    CrossRefPubMedWeb of Science
  15. 15.↵
    1. Mangla R,
    2. Singh G,
    3. Ziegelitz D,
    4. et al
    . Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology 2010;256:575–84
    CrossRefPubMedWeb of Science
  16. 16.↵
    1. Sanghera P,
    2. Perry J,
    3. Sahgal A,
    4. et al
    . Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. Can J Neurol Sci 2010;37:36–42
    PubMed
  17. 17.↵
    1. Clarke JL,
    2. Abrey LE,
    3. Karimi S,
    4. et al
    . Pseudoprogression (PsPr) after concurrent radiotherapy (RT) and temozolomide (TMZ) for newly diagnosed glioblastoma multiforme (GBM) [abstract]. J Clin Oncol 2008;26:2025
  18. 18.↵
    1. Gerstner ER,
    2. McNamara MB,
    3. Norden AD,
    4. et al
    . Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. J Neurooncol 2009;94:97–101
    CrossRefPubMed
  19. 19.↵
    1. Jefferies S,
    2. Burton K,
    3. Jones P,
    4. et al
    . Interpretation of early imaging after concurrent radiotherapy and temozolomide for glioblastoma [abstract]. Clin Oncol 2007;19:S33
  20. 20.↵
    1. Brandes AA,
    2. Tosoni A,
    3. Spagnolli F,
    4. et al
    . Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008;10:361–67. Epub 2008 Apr 9
    Abstract/FREE Full Text
  21. 21.↵
    1. Tsien C,
    2. Galbán CJ,
    3. Chenevert TL,
    4. et al
    . Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J Clin Oncol 2010;28:2293–99
    Abstract/FREE Full Text
  22. 22.↵
    1. Gahramanov S,
    2. Raslan AM,
    3. Muldoon LL,
    4. et al
    . Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrasted-enhanced magnetic resonance imaging using feruxomytol vs. gadoteridol: a pilot study. Int J Radiat Oncol Biol Phys 2011;79:514–23
    CrossRefPubMed
  23. 23.↵
    1. Clarke JL,
    2. Chang S
    . Pseudoprogression and pseudoresponse: challenges in brain tumor imaging. Curr Neurol Neurosci Rep 2009;9:241–46
    CrossRefPubMedWeb of Science
  24. 24.↵
    1. Sundgren PC,
    2. Fan X,
    3. Weybright P,
    4. et al
    . Differentiation of recurrent brain tumor versus radiation injury using diffusion tensor imaging in patients with new contrast enhancing lesions. Magn Reson Imaging 2006;24:1131–42
    CrossRefPubMedWeb of Science
  25. 25.↵
    1. Sundgren PC
    . MR spectroscopy in radiation injury. AJNR Am J Neuroradiol 2009;30:1469–76
    Abstract/FREE Full Text
  26. 26.↵
    1. Ricci PE,
    2. Karis JP,
    3. Heiserman JE,
    4. et al.
    , Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998;19:407–13
    Abstract
  27. 27.↵
    1. Hustinx R,
    2. Pourdehnad M,
    3. Kaschten B,
    4. et al
    . PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am 2005;43:35–47
    CrossRefPubMed
  28. 28.↵
    1. Batchelor TT,
    2. Sorensen AG,
    3. di Tomaso E,
    4. et al
    . AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007;11:83–95
    CrossRefPubMedWeb of Science
  29. 29.↵
    1. Pope WB,
    2. Lai A,
    3. Nghiemphu P,
    4. et al
    . MRI in patient with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 2006;66:1258–60
    Abstract/FREE Full Text
  30. 30.↵
    1. Norden AD,
    2. Young GS,
    3. Setayesh K,
    4. et al
    . Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779–87
    Abstract/FREE Full Text
  31. 31.↵
    1. Jain RK,
    2. Duda DG,
    3. Willett CG,
    4. et al
    . Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009;6:327–38
    CrossRefPubMedWeb of Science
  32. 32.↵
    1. Gerstner ER,
    2. Chen PJ,
    3. Wen PY,
    4. et al
    . Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib. Neuro Oncol 2010;12:466–72
    Abstract/FREE Full Text
  33. 33.↵
    1. Pope WB,
    2. Kim HJ,
    3. Huo J,
    4. et al
    . Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009;252:182–89
    CrossRefPubMedWeb of Science
  34. 34.↵
    1. Gerstner ER,
    2. Duda DG,
    3. di Tomaso E,
    4. et al
    . VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat Rev Clin Oncol 2009;6:229–36
    CrossRefPubMed
  35. 35.↵
    1. Sorensen AG,
    2. Batchelor TT,
    3. Zhang WT,
    4. et al
    . A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009;69:5296–300
    Abstract/FREE Full Text
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 32 (11)
American Journal of Neuroradiology
Vol. 32, Issue 11
1 Dec 2011
  • Table of Contents
  • Index by author
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
L.C. Hygino da Cruz, I. Rodriguez, R.C. Domingues, E.L. Gasparetto, A.G. Sorensen
American Journal of Neuroradiology Dec 2011, 32 (11) 1978-1985; DOI: 10.3174/ajnr.A2397

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma
L.C. Hygino da Cruz, I. Rodriguez, R.C. Domingues, E.L. Gasparetto, A.G. Sorensen
American Journal of Neuroradiology Dec 2011, 32 (11) 1978-1985; DOI: 10.3174/ajnr.A2397
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS
    • Macdonald Criteria
    • Patterns of Early Enhancement in Posttreatment MR Imaging Follow-Up
    • Radiation Injury
    • Pseudoprogression
    • O6-Methylguanine DNA MGMT Promoter
    • Incidence
    • Pathophysiology
    • Diagnosis
    • Advanced MR Imaging Techniques
    • PET
    • Clinical Management
    • Conclusions
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • References
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Spatiotemporal Heterogeneity in Multiparametric Physiologic MRI Is Associated with Patient Outcomes in IDH-Wildtype Glioblastoma
  • 18F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience
  • A comprehensive proteomic SWATH-MS workflow for profiling blood extracellular vesicles: a new avenue for glioma tumour surveillance
  • Dynamic Contrast-Enhanced MRI in Patients with Brain Metastases Undergoing Laser Interstitial Thermal Therapy: A Pilot Study
  • Non-Contrast-Enhancing Tumor: A New Frontier in Glioblastoma Research
  • Radiogenomics-based Risk Prediction of Glioblastoma Multiforme with Clinical Relevance
  • Synthesizing a Contrast-Enhancement Map in Patients with High-Grade Gliomas Based on a Postcontrast MR Imaging Quantification Only
  • Radiomics in Brain Tumor: Image Assessment, Quantitative Feature Descriptors, and Machine-Learning Approaches
  • Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas
  • Detection of immune responses after immunotherapy in glioblastoma using PET and MRI
  • Multiparametric Evaluation in Differentiating Glioma Recurrence from Treatment-Induced Necrosis Using Simultaneous 18F-FDG-PET/MRI: A Single-Institution Retrospective Study
  • Preradiotherapy MR Imaging: A Prospective Pilot Study of the Usefulness of Performing an MR Examination Shortly before Radiation Therapy in Patients with Glioblastoma
  • Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas
  • Temozolomide induces radiologic pseudoprogression and tumor cell vanishing in oligodendroglioma
  • Late Pseudoprogression in Glioblastoma: Diagnostic Value of Dynamic O-(2-[18F]fluoroethyl)-L-Tyrosine PET
  • Differentiating Tumor Progression from Pseudoprogression in Patients with Glioblastomas Using Diffusion Tensor Imaging and Dynamic Susceptibility Contrast MRI
  • Parametric Response Mapping of Apparent Diffusion Coefficient as an Imaging Biomarker to Distinguish Pseudoprogression from True Tumor Progression in Peptide-Based Vaccine Therapy for Pediatric Diffuse Intrinsic Pontine Glioma
  • Repeatability of Standardized and Normalized Relative CBV in Patients with Newly Diagnosed Glioblastoma
  • Radiation Necrosis in Pediatric Patients with Brain Tumors Treated with Proton Radiotherapy
  • Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
  • Differentiation of Tumor Progression from Pseudoprogression in Patients with Posttreatment Glioblastoma Using Multiparametric Histogram Analysis
  • In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma
  • Longitudinal Restriction Spectrum Imaging Is Resistant to Pseudoresponse in Patients with High-Grade Gliomas Treated with Bevacizumab
  • Response Classification Based on a Minimal Model of Glioblastoma Growth Is Prognostic for Clinical Outcomes and Distinguishes Progression from Pseudoprogression
  • Imaging Changes in Very Young Children with Brain Tumors Treated with Proton Therapy and Chemotherapy
  • Multimodal Magnetic Resonance Imaging and 18F-L-Dihydroxyphenylalanine Positron Emission Tomography in Early Characterization of Pseudoresponse and Nonenhancing Tumor Progression in a Pediatric Patient With Malignant Transformation of Ganglioglioma Treated With Bevacizumab
  • Metabolic Response of Glioblastoma to Superselective Intra-Arterial Cerebral Infusion of Bevacizumab: A Proton MR Spectroscopic Imaging Study
  • Late and Prolonged Pseudoprogression in Glioblastoma After Treatment With Lomustine and Temozolomide
  • Crossref
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

More in this TOC Section

  • Mechanisms of Healing in Coiled Intracranial Aneurysms: A Review of the Literature
  • Ultra-High-Field MR Neuroimaging
  • 4D-CTA in Neurovascular Disease: A Review
Show more Review Articles

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2020 Distinguished Reviewers
  • Press Releases

Resources

  • Evidence-Based Medicine Level Guide
  • How to Participate in a Tweet Chat
  • AJNR Podcast Archive
  • Ideas for Publicizing Your Research
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Share Your Art in Perspectives
  • Get Peer Review Credit from Publons
  • Moderate a Tweet Chat

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal
  • Position Statements

© 2021 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire